Study Condition(s): Adult Type 2 Diabetes

A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

Study Alias: ABER

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT02302716 {{ currentLocaleObject.registryAnchorText }}

Completed Completed

Study Purpose

The main purpose of this study is to evaluate the safety and efficacy of the study drug known as LY2963016 as compared to LANTUS® in adults with type 2 diabetes mellitus who are on 2 or more oral antihyperglycemic medications (OAMs).

Completed Study

The results of this study are not yet available.

Who Participated? Tool Tip Icon

Here you can find out a bit more about the requirements for volunteers who took part in this study

Gender

Male Female

Age

18+ years

Time Commitment

Your participation in this trial could last up to 28 weeks and include 9 visits to the study center
  • Participant must have type 2 diabetes mellitus (T2DM)and be capable and willing to perform self monitored blood glucose (SMBG), complete participant diaries as instructed, are receptive to diabetes education, and comply with required study treatment and study visits

  • Participant must not have taken basal plus mealtime insulin (basal bolus therapy) within the last year for greater than 4 continuous weeks

  • Participant must not have more than 1 episode of severe hypoglycemia within 6 months prior to screening

  • Participant must not have had 2 or more emergency room visits or hospitalizations due to poor glucose control in the 6 months prior to screening

  • Participant must not have known hypersensitivity or allergy to LANTUS®;

  • Participant must not have obvious signs or symptoms of liver disease, significant cardiac or gastrointestinal disease, history of kidney transplant or dialysis, or HIV

  • Participant must not have had a blood transfusion or severe blood loss within 3 months prior to screening

  • Participants must not have active cancer or personal history of cancer within the previous 5 years (with the exception of basal cell carcinoma or carcinoma in situ)

  • Participant must not be breastfeeding, pregnant or intend to become pregnant during the course of the study

Where This Study Took Place Tool Tip Icon

52 locations participated
Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Closest Location
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Other Location(s)
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.